Kaizen Pharmaceuticals Secures Approval for Cytotoxic Liquid Injectables

Kaizen Pharmaceuticals is proud to have also received approval to manufacture 𝐂𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜 𝐋𝐢𝐪𝐮𝐢𝐝 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 through its advanced, high-tech Oncology manufacturing facility. This approval enables the local aseptic production of 𝐫𝐞𝐚𝐝𝐲-𝐭𝐨-𝐝𝐢𝐥𝐮𝐭𝐞 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, helping widen patient access while reducing dependence on imported treatments and the associated foreign exchange burden. Backed by stringent sterility, containment, and quality systems, this capability will support stronger affordability, supply continuity, and greater resilience in Pakistan’s oncology care landscape. A proud achievement, bringing hope closer to cancer patients across Pakistan.